Clinical decision on a patient with ALK+ diffuse large B cell lymphoma

Ling Dong, Bin Meng, Xinwei Zhang, Xiuyu Song, Ximei Zhang, Qiongli Zhai, Xia Liu, Yun Hou, Wei Li, Xianhuo Wang, Huaqing Wang, Kai Fu, Huilai Zhang

Research output: Contribution to journalArticle

Abstract

Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare and distinct variant of DLBCL. It is classified as a unique subtype of DLBCL in the 2008 WHO classification of lymphomas. No standard and effective therapeutic regimen is available for ALK+DLBCL because it shows a more aggressive clinical course and frequent relapse. Therefore, a standardized and individualized treatment is needed to benefit more patients diagnosed with ALK+DLBCL through a multiple disciplinary team. This article presents a case of an ALK+DLBCL patient who relapsed after transplantation and was successfully treated with the ALK kinase inhibitor Crizotinib.

Original languageEnglish (US)
Pages (from-to)385-391
Number of pages7
JournalChinese Journal of Clinical Oncology
Volume43
Issue number9
DOIs
StatePublished - Jan 1 2016

    Fingerprint

Keywords

  • Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (ALK + DLBCL)
  • Crizotinib
  • Multiple disciplinary team (MDT)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dong, L., Meng, B., Zhang, X., Song, X., Zhang, X., Zhai, Q., Liu, X., Hou, Y., Li, W., Wang, X., Wang, H., Fu, K., & Zhang, H. (2016). Clinical decision on a patient with ALK+ diffuse large B cell lymphoma. Chinese Journal of Clinical Oncology, 43(9), 385-391. https://doi.org/10.3969/j.issn.1000-8179.2016.09.350